MedNet.nl: Bicistronic CD19/CD22-targeted CAR T-cell therapy appears to be a safe and effective regimen that results in durable remission in children with relapsing or refractory B-cell acute lymphoblastic leukemia (B-ALL).
09-12-2024 | Acute Lymphoblastic Leukemia | News